Company name: Pursuit Vascular Inc.
Industry: Medical Devices.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Location: Blaine, Minnesota.
Product: Its ClearGuard HD device is used to prevent infection associated with hemodialysis catheters.
Money raised: $1.3 million, seeking $2 million. CEO expects that because the round is oversubscribed, more than $2 million will be raised. Company has raised $1 million by issuing convertible debt previously.
How it will be used: For “regulatory clearance, intellectual property and clinical trial preparation activities associated with our novel ClearGuard HD device,” said CEO Doug Killion. Earlier, Killion had hoped for a mid-2012 market clearance.
Investors: Angels and midsize venture capital firms including Omphalos Venture Partners.
Management team: Doug Killion, CEO; Robert Ziebol, chief technology officer; Keith Modert, director of engineering; and Robert Weinmann, medical director.
Market size: Worldwide market for the ClearGuard HD device is more than $500 million, according to Killion.
Competitors: European companies making antimicrobial fluids for catheters such as Dirinco, which makes Citra-Lock; Geistlich Medical, which makes TauroSept; and Tauro-Implant, which manufactures TauroLock.